（编辑 丛可心） 证券日报网1月6日讯 ，康希诺在接受调研者提问时表示，公司的创新型婴幼儿用联苗DTcP-Hib-MCV4 已于2025年2月获得临床试验批准，并于同年12月启动I期临床试验，以评估其在2月龄~6岁人群中接种 的安全性及免疫原性，与现有已上市及在研联苗产品形成差异化竞争。该联苗从临床需求的角度出发， 考量了婴幼儿所需接种的疫苗品类，预期未来可提升婴幼儿群体接种的便利性和依从性。未来如有阶段 性试验数据，公司也将及时与市场沟通。公司也将综合考量现有的疫苗组合以及婴幼儿预防接种的临床 需求，探索其它适用于当前免疫接种需求的候选联苗，扩大公司产品的影响力。 ...

Core Viewpoint - The company, CanSino, has successfully positioned its product, Manhaixin®, as the only approved quadrivalent meningococcal conjugate vaccine in China, targeting the mid-to-high-end infant vaccine market, with increasing market acceptance and sales growth indicating strong demand for high-quality vaccines in the domestic market [1] Group 1: Product Development and Market Expansion - Manhaixin® has seen steady sales growth, confirming the demand for premium infant vaccines in China [1] - The company has submitted a supplementary application to expand the age indication for Manhaixin® to children aged 3 months to 6 years and plans to pursue further age expansion for adolescents and adults (ages 7 to 59) [1] - The product has been launched in Indonesia as of September 2025, marking the start of its sales in the local market [1] - The company is actively working to expand the product's market access in other target countries and regions to enhance its influence and benefit a broader population [1] Group 2: Financial Performance - For the third quarter of 2025, the company reported revenue of approximately 693 million yuan, representing a year-on-year increase of 22% [1] - The sales revenue from the meningococcal product reached approximately 662 million yuan in the first three quarters, reflecting a 28% increase compared to the same period last year [1] - The company has announced a new equity incentive plan with revenue growth targets set for 2025, indicating a commitment to achieving these objectives [1]

Core Viewpoint - The company, CanSino, has been deeply engaged in key areas such as meningitis vaccines, pneumonia vaccines, infant vaccines, innovative vaccination schemes, and adult vaccines for many years, and plans to continue enriching its pipeline through advanced technology platforms [1] Group 1: Current Focus Areas - The company is exploring innovative fields and expanding into areas such as tumor vaccines and therapeutic vaccines, aiming to develop differentiated competitive products [1] - mRNA technology is one of the company's leading platforms, recognized for its high platform value and broad development prospects [1] Group 2: Research and Development - The company has accumulated years of experience in the development and production of mRNA vaccines, including in-depth knowledge of infectious diseases and antigen screening [1] - In the therapeutic area, the company is advancing the development of mRNA vaccines for glioblastoma and rhabdomyosarcoma, aiming to expand the application range of its leading technology platform [1] Group 3: Technology and Licensing - The company has achieved external technology licensing for its proprietary new three-component lipid nanoparticle delivery system (ISL-3C-LNP) [1]

Core Viewpoint - The company, CanSino, is focusing on its core business while exploring additional indications in the treatment field using its mRNA technology platform, with updates to be provided upon significant progress [1]. Group 1 - CanSino is committed to enhancing its main business operations [1]. - The company is leveraging its mRNA technology platform for further exploration in treatment indications [1]. - CanSino will announce any significant advancements in its research and development efforts in a timely manner [1].

Group 1 - The core point of the article is that CanSino Biologics has stated that since mid-April 2021, the China National Medical Products Administration (NMPA) no longer publishes the batch release numbers for vaccine products, and the company will follow the information disclosure practices of its peers [1] Group 2 - CanSino Biologics is adapting its information disclosure strategy in response to regulatory changes regarding vaccine batch release data [1]

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

康希诺生物(6185.HK)今日盘中一度涨3.74%至37.74港元，股价创2025年12月16日以来新高；该股2026年实现开门红，迄今已连续三个交易日上涨，累涨超 8%，跑赢大盘表现(同期恒指累涨超4%)。 康希诺生物昨日晚间公告，公司研发的24价肺炎球菌多糖结合疫苗(CRM197╱破伤风类毒素)("PCV24")已获得中国国家药品监督管理局批准，可以开展相关 临床试验。公司PCV24覆盖当前肺炎球菌主要流行血清型，采用多糖抗原与蛋白载体共价结合的方式，以及双载体技术，拟适用于2月龄(最小6周)及以上人 群接种，以预防由24种肺炎球菌血清型引起的感染性疾病。该产品完成了24种血清型纯化多糖、多糖蛋白结合物原液生产工艺、成品处方的开发与确认。于 本公告日期，24价肺炎球菌多糖结合疫苗在国内外均无上市产品。(格隆汇) ...

每经AI快讯，康希诺生物(06185.HK)一度涨超3%，截至发稿涨2.8%，报37.4港元，成交额3299.01万港 元。 （文章来源：每日经济新闻） ...

消息面上，1月5日，康希诺生物发布公告，公司研发的24价肺炎球菌多糖结合疫苗(CRM197╱破伤风 类毒素)(PCV24)已获得中国国家药品监督管理局批准，可以开展相关临床试验。 康希诺生物(06185)涨超3%，截至发稿，涨2.8%，报37.4港元，成交额3299.01万港元。 公司PCV24覆盖当前肺炎球菌主要流行血清型，採用多糖抗原与蛋白载体共价结合的方式，以及双载体 技术，拟适用于2月龄(最小6周)及以上人群接种，以预防由24种肺炎球菌血清型引起的感染性疾病。该 产品完成了24种血清型纯化多糖、多糖蛋白结合物原液生产工艺、成品处方的开发与确认。于本公告日 期，24价肺炎球菌多糖结合疫苗在国内外均无上市产品。 ...

智通财经APP获悉，康希诺生物(06185)涨超3%，截至发稿，涨2.8%，报37.4港元，成交额3299.01万港 元。 消息面上，1月5日，康希诺生物发布公告，公司研发的24价肺炎球菌多糖结合疫苗(CRM197╱破 伤风类毒素)(PCV24)已获得中国国家药品监督管理局批准，可以开展相关临床试验。 公司PCV24覆盖当前肺炎球菌主要流行血清型，採用多糖抗原与蛋白载体共价结合的方式，以及双载体 技术，拟适用于2月龄(最小6周)及以上人群接种，以预防由24种肺炎球菌血清型引起的感染性疾病。该 产品完成了24种血清型纯化多糖、多糖蛋白结合物原液生产工艺、成品处方的开发与确认。于本公告日 期，24价肺炎球菌多糖结合疫苗在国内外均无上市产品。 ...